SEC Comment Letter 0000000000-24-003280 to Mineralys Therapeutics, Inc. (MLYS) (CIK 0001933414) (MLYS)
Mineralys Therapeutics, Inc. (MLYS) (CIK 0001933414)
Date: March 26, 2024 · CIK: 0001933414 · Accession: 0000000000-24-003280
AI Filing Summary & Sentiment
File numbers found in text: 333-278122
Letter
United States securities and exchange commission logo March 26, 2024 Jon Congleton Chief Executive Officer Mineralys Therapeutics, Inc. 150 N. Radnor Chester Road, Suite F200 Radnor, PA 19087 Re:Mineralys Therapeutics, Inc. Registration Statement on Form S-3 Filed March 21, 2024 File No. 333-278122 Dear Jon Congleton: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Griffin D. Foster, Esq.
Show Raw Text
United States securities and exchange commission logo
March 26, 2024
Jon Congleton
Chief Executive Officer
Mineralys Therapeutics, Inc.
150 N. Radnor Chester Road, Suite F200
Radnor, PA 19087
Re:Mineralys Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 21, 2024
File No. 333-278122
Dear Jon Congleton:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Griffin D. Foster, Esq.